BREAST SPORE-RELATED PUBLICATIONS
Olufunmilayo Olopade, MBBS
Chen Y, Olopade OI. MYC in breast tumor progression. Expert Rev Anticancer Ther 8:1689-98, 2008.
PMC3027840
Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine.
Clin Cancer Res 14:7988-99, 2008.
*Li H, Giger ML, Olopade OI, Chinander MR. Power spectral analysis of mammographic parenchymal patterns
for breast cancer risk assessment. J Digit Imaging 21:145-52, 2008. PMC3043857
*Belova L, Delgado B, Kocherginsky M, Melhem A, Olopade OI, Conzen SD. Glucocorticoid receptor
expression in breast cancer associates with older patient age. Breast Cancer Res Treat 116:441-7, 2009.
Wang X, Liu L, Fackenthal J, Cummings S, Olopade OI, Hope K, Silverstein JC. Translational integrity and
continuity: personalized biomedical data integration. J Biomed Inform 42:100-12, 2009. PMC2675887
*Medved M, Newstead GM, Fan X, Du YP, Olopade OI, Shimauchi A, Zamora MA, Karczmar GS. Fourier
component imaging of water resonance in the human breast provides markers for malignancy.
Phys Med Biol 54:5767-79, 2009. PMC2941263
Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O,
Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI. Population
differences in breast cancer: survey in indigenous African women reveals over-representation of triplenegative breast cancer. J Clin Oncol 27:4515-21, 2009. PMC2754904
*Medved M, Newstead GM, Abe H, Olopade OI, Shimauchi A, Zamora MA, Karczmar GS. Clinical
implementation of a multislice high spectral and spatial resolution-based MRI sequence to achieve
unilateral full-breast coverage. Magn Reson Imaging 28:16-21, 2010. PMC2789876
*Sun C, Olopade OI, Di Rienzo A. rs2981582 is associated with FGFR2 expression in normal breast.
Cancer Genet Cytogenet 197:193-4, 2010. PMC2831800
*Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway
activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176:2911-20,
2010. PMC2877852
Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI. Screening RAD51C nucleotide alterations in patients
with a family history of breast and ovarian cancer. Breast Cancer Res Treat 124:857-61, 2010.
*Medved M, Ivancevic MK, Olopade OI, Newstead GM, Karczmar GS. Echo-planar spectroscopic imaging
(EPSI) of the water resonance structure in human breast using sensitivity encoding (SENSE).
Magn Reson Med 63:1557-63, 2010. PMC3065325
Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, Jonasdottir A, Besenbacher S,
Kostic JP, Fackenthal JD, Huo D, Adebamowo C, Ogundiran T, Olson JE, Fredericksen ZS, Wang X,
Look MP, Sieuwerts AM, Martens JW, Pajares I, Garcia-Prats MD, Ramon-Cajal JM, de Juan A,
Panadero A, Ortega E, Aben KK, Vermeulen SH, Asadzadeh F, van Engelenburg KC, Margolin S,
Shen CY, Wu PE, Försti A, Lenner P, Henriksson R, Johansson R, Enquist K, Hallmans G, Jonsson T,
Sigurdsson H, Alexiusdottir K, Gudmundsson J, Sigurdsson A, Frigge ML, Gudmundsson L,
Kristjansson K, Halldorsson BV, Styrkarsdottir U, Gulcher JR, Hemminki K, Lindblom A, Kiemeney LA,
Mayordomo JI, Foekens JA, Couch FJ, Olopade OI, Gudbjartsson DF, Thorsteinsdottir U, Rafnar T,
Johannsson OT, Stefansson K. Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer
susceptibility locus. PLoS Genet 6:e1001029, 2010. PMC2908678
Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyesegun R, Akang E, Adebamowo C, Olopade OI.
Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol 172:682-90,
2010. PMC2950817
*Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA,
Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and
increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat 119:137-44, 2010.
*Sun C, Southard C, Witonsky DB, Olopade OI, Di Rienzo A. Allelic imbalance (AI) identifies novel tissuespecific cis-regulatory variation for human UGT2B15. Hum Mutat 31:99-107, 2010. PMC2922057
Jansen SA, Fan X, Medved M, Abe H, Shimauchi A, Yang C, Zamora M, Foxley S, Olopade OI, Karczmar GS,
Newstead GM. Characterizing early contrast uptake of ductal carcinoma in situ with high temporal
resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys Med Biol 55:N473-85, 2010.
*Xu J, Chen Y, Olopade OI. MYC and breast cancer. Genes Cancer 1:629-40, 2010. PMC3092228
Page 1
*Sun C, Southard C, Olopade OI, Di Rienzo A. Differential allelic expression of c.1568C > A at UGT2B15 is
due to variation in a novel cis-regulatory element in the 3'UTR. Gene 481:24-8, 2011. PMC3105206
*Huo D, Melkonian S, Rathouz PJ, Khramtsov A, Olopade OI. Concordance in histological and biological
parameters between first and second primary breast cancers. Cancer 117:907-15, 2011. PMC3022996
*Sun C, Huo D, Southard C, Nemesure B, Hennis A, Cristina Leske M, Wu SY, Witonsky DB, Olopade OI,
Di Rienzo A. A signature of balancing selection in the region upstream to the human UGT2B4 gene and
implications for breast cancer risk. Hum Genet 130:767-75, 2011.
Chen Y, Xu J, Borowicz S, Collins C, Huo D, Olopade OI. c-Myc activates BRCA1 gene expression through
distal promoter elements in breast cancer cells. BMC Cancer 11:246, 2011. PMC3141769
Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y,
Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ. Proliferating
macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical
outcome. Breast Cancer Res Treat 128:703-11, 2011.
Medved M, Fan X, Abe H, Newstead GM, Wood AM, Shimauchi A, Kulkarni K, Ivancevic MK, Pesce LL,
Olopade OI, Karczmar GS. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of
non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fatsuppressed images. Acad Radiol 18:1467-74, 2011. PMC3210583
*Sun C, Huo D, Nemesure B, Hennis A, Leske MC, Wu SY, Niu Q, Olopade OI, Di Rienzo A. Lack of
association between common UGT2B nonsynonymous single-nucleotide polymorphisms and breast cancer
in populations of African ancestry. Int J Cancer 130:2740-2, 2012. PMC3268011
*Ulasov IV, Kaverina NV, Pytel P, Thaci B, Liu F, Hurst DR, Welch DR, Sattar HA, Olopade OI,
Baryshnikov AY, Kadagidze ZG, Lesniak MS. Clinical significance of KISS1 protein expression for brain
invasion and metastasis. Cancer 118:2096-105, 2012. PMC3674482
*Zheng Y, Zhang J, Niu Q, Huo D, Olopade OI. Novel germline PALB2 truncating mutations in African
American breast cancer patients. Cancer 118:1362-70, 2012. PMC3244533
* *Sylvester BE, Huo D, Khramtsov A, Zhang J, Smalling RV, Olugbile S, Polite BN, Olopade OI. Molecular
analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res 18:3509, 2012. PMC3272273
*Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Rebbeck TR, Simon MS, John EM,
Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, Niu Q, Zhang J, Cox NJ, Olopade OI, Huo D. Lack of
association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast
cancer in women of African ancestry. Breast Cancer Res Treat 132:341-5, 2012. PMC3670987
Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K,
Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L,
Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D,
Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, I-SPY 1 Trial Investigators. Chemotherapy
response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results
from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 132:1049-62,
2012. PMC3332388
Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C,
Nobel A, Kristensen VN, Borresen-Dale AL, Olopade OI, Perou CM. Basal-like breast cancer DNA copy
number losses identify genes involved in genomic instability, response to therapy, and patient survival.
Breast Cancer Res Treat 133:865-80, 2012. PMC3387500
*Zheng Y, Huo D, Zhang J, Yoshimatsu TF, Niu Q, Olopade OI. Microsatellites in the estrogen receptor (ESR1,
ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian
women. PLoS One 7:e40494, 2012. PMC3394707
*Sun C, Southard C, Huo D, Hernandez RD, Witonsky DB, Olopade OI, Di Rienzo A. SNP discovery,
expression and cis-regulatory variation in the UGT2B genes. Pharmacogenomics J 12:287-96, 2012.
Li H, Giger ML, Lan L, Bancroft Brown J, Macmahon A, Mussman M, Olopade OI, Sennett C. Computerized
analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital
mammograms: robustness study with two high-risk datasets. J Digit Imaging 25:591-8, 2012.
PMC3447101
Page 2
Esserman LJ, Berry DA, Demichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C,
Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT,
Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic
complete response predicts recurrence-free survival more effectively by cancer subset: results from the
I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. PMC3434983
Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A,
Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M,
Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai
L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive
trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin
Oncol 30:4584-6, 2012.
Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos, F, Burrill DR, Niu Q, Huo D, Sveen WE, Ogundiran T,
Adebamowo C, Odetunde A, Falusi AG, Olopade OI. High prevalence of BRCA1 and BRCA2 mutations in
unselected Nigerian breast cancer patients. Int J Cancer 131:1114-23, 2012.
Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC,
Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic
breast cancer. Breast Cancer Res Treat 136:355-63, 2012. PMC3658119
Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyesegun R, Akang E, Adebamowo C, Olopade OI. Body
fat distribution and breast cancer risk: findings from the Nigerian breast cancer study. Cancer Causes
Control 23:565-74, 2012.
Wood AM, Medved M, Bacchus ID, Al-Hallaq HA, Shimauchi A, Newstead GM, Olopade OI,
Venkataraman SS, Ivancevic MK, Karczmar GS. Classification of breast lesions pre-contrast injection using
water resonance lineshape analysis. NMR Biomed 26:569-77, 2013.
Baretta Z, Guindalini RS, Khramtsova G, Olopade OI. Resistance to trastuzumab in HER2-positive mucinous
invasive ductal breast carcinoma. Clin Breast Cancer 13:156-8, 2013.
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T,
Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c inhibits
human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 4:1393, 2013.
PMC3723106
Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, Baek S, Hunter K, Yang H, Lee M, Zvosec C,
Khramtsova G, Cheng F, Perou CM, Ryan Miller C, Raab R, Olopade OI, Gardner K. Genome-wide
profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat
Commun 4:1449, 2013. PMC3768144
Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM,
Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast
cancer cell invasion. Breast Cancer Res Treat 137:373-82, 2013. PMC3583223
Chen F, Chen GK, Stram DO, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Palmer JR,
Hu JJ, Rebbeck TR, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Press MF, Ruiz-Narvaez EA,
Deming SL, Rodriguez-Gil JL, Demichele A, Chanock SJ, Blot W, Signorello L, Cai Q, Li G, Long J, Huo D,
Zheng Y, Cox NJ, Olopade OI, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Simon MS,
Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, Hutter CM, Young A, Kooperberg C, Peters U,
Rhie SK, Wan P, Sheng X, Pooler LC, Van Den Berg DJ, Le Marchand L, Kolonel LN, Henderson BE,
Haiman CA. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet
132:39-48, 2013. PMC3749077
Zheng Y, Ogundiran TO, Falusi AG, Nathanson KL, John EM, Hennis AJ, Ambs S, Domchek SM,
Rebbeck TR, Simon MS, Nemesure B, Wu SY, Leske MC, Odetunde A, Niu Q, Zhang J, Afolabi C,
Gamazon ER, Cox NJ, Olopade CO, Olufunmilayo OI, Huo D. Fine-mapping of breast cancer genomewide association studies loci in women of African ancestry identifies novel susceptibility markers.
Carcinogenesis 34:1520-8, 2013. PMC3697898
Suzanne Conzen, MD
*Belova L, Delgado B, Kocherginsky M, Melhem A, Olopade OI, Conzen SD. Glucocorticoid receptor
expression in breast cancer associates with older patient age. Breast Cancer Res Treat 116:441-7, 2009.
Page 3
Luca F, Kashyap S, Southard C, Zou M, Witonsky D, Di Rienzo A, Conzen SD. Adaptive variation regulates
the expression of the human SGK1 gene in response to stress. PLoS Genet 5:e1000489, 2009.
PMC2679193
*Jansen SA, Conzen SD, Fan X, Markiewicz EJ, Newstead GM, Karczmar GS. Magnetic resonance imaging of
the natural history of in situ mammary neoplasia in transgenic mice: a pilot study. Breast Cancer Res
11:R65, 2009. PMC2790840
*Jansen SA, Conzen SD, Fan X, Markiewicz E, Krausz T, Newstead GM, Karczmar GS. In vivo MRI of early
stage mammary cancers and the normal mouse mammary gland. NMR Biomed 24:880-7, 2011.
*Hipp E, Fan X, Jansen SA, Markiewicz EJ, Vosicky J, Newstead GM, Conzen SD, Krausz T, Karczmar GS.
T(2) relaxation times of intraductal murine mammary cancer, invasive mammary cancer, and normal
mammary gland. Med Phys 39:1309-13, 2012. PMC3292598
Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC,
Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic
breast cancer. Breast Cancer Res Treat 136:355-63, 2012. PMC3658119
Makinen MW, Bamba R, Ikejimba L, Wietholt C, Chen CT, Conzen SD. The vanadyl chelate
bis(acetylacetonato)oxovanadium(IV) increases the fractional uptake of2-(fluorine-18)-2-deoxy-D-glucose
by cultured human breast carcinoma cells. Dalton Trans 42:11862-7, 2013. PMC3733664
Nancy Cox, PhD
*Gamazon ER, Zhang W, Huang RS, Dolan ME, Cox NJ. A pharmacogene database enhanced by the 1000
Genomes Project. Pharmacogenet Genomics 19:829-32, 2009. PMC2935084
Huang RS, Chen P, Wisel S, Duan S, Zhang W, Cook EH, Das S, Cox NJ, Dolan ME. Population-specific
GSTM1 copy number variation. Hum Mol Genet 18:366-72, 2009. PMC2722188
*Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, Dolan ME, Cox NJ. SCAN: SNP
and copy number annotation. Bioinformatics 26:259-62, 2010. PMC2852202
*Gamazon ER, Zhang W, Dolan ME, Cox NJ. Comprehensive survey of SNPs in the Affymetrix exon array
using the 1000 Genomes dataset. PLoS One 5:e9366, 2010. PMC2826392
*Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs are more likely to be
eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 6:e1000888, 2010. PMC2848547
*Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are
enriched in expression quantitative trait loci. Proc Natl Acad Sci 107:9287-92, 2010. PMC2889115
Gamazon ER, Im HK, Duan S, Lussier YA, Cox NJ, Dolan ME, Zhang W. Exprtarget: an integrative approach
to predicting human microRNA targets. PLoS One 5:e13534, 2010. PMC2958831
*Chen SH, Pei D, Yang W, Cheng C, Jeha S, Cox NJ, Evans WE, Pui CH, Relling MV. Genetic variations in
GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther 88:191-6,
2010. PMC3000799
Stark AL, Zhang W, O’Donnell PH, Beiswanger CM, Huang RS, Cox NJ, Dolan ME. Population differences in
rate of proliferation of international HapMap cell lines. Am J Hum Genet 87:829-33, 2010. PMC2997375
Gamazon ER, Duan S, Zhang W, Huang RS, Kistner EO, Dolan ME, Cox NJ. PACdb: a database for cellbased pharmacogenomics. Pharmacogenet Genomics 20:269-73, 2010. PMC2914089
*Gamazon ER, Nicolae DL, Cox NJ. A study of CNVs as trait-associated polymorphisms and as expression
quantitative trait loci. PLoS Genet 7:e1001292, 2011. PMC3033384
Wheeler HE, Gorsic LK, Welsh M, Stark AL, Gamazon ER, Cox NJ, Dolan ME. Genome-wide local ancestry
approach identifies genes and variants associated with chemotherapeutic susceptibility in African
Americans. PLoS One 6:e21920, 2011. PMC3130766
Gamazon ER, Im HK, O’Donnell PH, Ziliak D, Stark AL, Cox NJ, Dolan ME, Huang RS. Comprehensive
evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther 10:472-80,
2011. PMC3079551
Gamazon ER, Huang RS, Dolan ME, Cox NJ. Copy number polymorphisms and anticancer
pharmacogenomics. Genome Biol 12:R46, 2011. PMC3219969
Ziliak D, O’Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE,
Cohen EE, Dolan ME, Huang RS. Germline polymorphisms discovered via a cell-based genome-wide
approach predict platinum response in head and neck cancers. Transl Res 157:265-72, 2011.
PMC3079878
Page 4
Huang RS, Johnatty SE, Gamazon ER, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S,
O’Donnell PH, Fraiman YS, Das S, Cox NJ, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall E,
Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E,
Vergote I, Gross J, Karlan BY, deFazio A, Chenevix-Trench G, Australian Ovarian Cancer Study Group,
Dolan ME. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and
analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 17:5490-500, 2011.
PMC3160494
*Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Rebbeck TR, Simon MS, John EM,
Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, Niu Q, Zhang J, Cox NJ, Olopade OI, Huo D. Lack of
association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast
cancer in women of African ancestry. Breast Cancer Res Treat 132:341-5, 2012. PMC3670987
Im HK, Gamazon ER, Stark AL, Huang RS, Cox NJ, Dolan ME. Mixed effects modeling of proliferation rates in
cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet 8:e1002525, 2012.
PMC3276560
O’Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, Gorsic L, Im HK, Huang RS, Cox NJ,
Dolan ME. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer
118:4063-73, 2012. PMC3413892
Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I,
Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, Cox NJ,
Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture
of paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 19:491-9, 2013. PMC3549006
Wheeler HE, Gamazon ER, Stark AL, O’Donnell PH, Gorsic LK, Huang RS, Cox NJ, Dolan ME. Genome-wide
meta-analysis identifies variants associated with platinating agent susceptibility across populations.
Pharmacogenomics J 13:35-43, 2013. PMC3370147
Chen F, Chen GK, Stram DO, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Palmer JR,
Hu JJ, Rebbeck TR, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Press MF, Ruiz-Narvaez EA,
Deming SL, Rodriguez-Gil JL, Demichele A, Chanock SJ, Blot W, Signorello L, Cai Q, Li G, Long J, Huo D,
Zheng Y, Cox NJ, Olopade OI, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Simon MS,
Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, Hutter CM, Young A, Kooperberg C, Peters U,
Rhie SK, Wan P, Sheng X, Pooler LC, Van Den Berg DJ, Le Marchand L, Kolonel LN, Henderson BE,
Haiman CA. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet
132:39-48, 2013. PMC3749077
Zheng Y, Ogundiran TO, Falusi AG, Nathanson KL, John EM, Hennis AJ, Ambs S, Domchek SM,
Rebbeck TR, Simon MS, Nemesure B, Wu SY, Leske MC, Odetunde A, Niu Q, Zhang J, Afolabi C,
Gamazon ER, Cox NJ, Olopade CO, Olufunmilayo OI, Huo D. Fine-mapping of breast cancer genomewide association studies loci in women of African ancestry identifies novel susceptibility markers.
Carcinogenesis 34:1520-8, 2013. PMC3697898
Gamazon ER, Huang RS, Dolan ME, Cox N, Im HK. Integrative genomics: quantifying significance of
phenotype-genotype relationships from multiple sources of high-throughput data. Front Genet 3:202, 2013.
PMC3668276
˄
Shelly Cummings, MS
Wang X, Liu L, Fackenthal J, Cummings S, Olopade OI, Hope K, Silverstein JC, Olopade OI. Translational
integrity and continuity: personalized biomedical data integration. J Biomed Inform 42:100-12, 2009.
PMC2675887
˄
Anna Di Rienzo, PhD
*Sun C, Di Rienzo A. UGT2B7 is not expressed in normal breast. Breast Cancer Res Treat 117:225-6, 2009.
PMC2921443
Luca F, Kashyap S, Southard C, Zou M, Witonsky D, Di Rienzo A, Conzen SD. Adaptive variation regulates
the expression of the human SGK1 gene in response to stress. PLoS Genet 5:e1000489, 2009.
PMC2679193
*Sun C, Southard C, Witonsky DB, Olopade OI, Di Rienzo A. Allelic imbalance (AI) identifies novel tissuespecific cis-regulatory variation for human UGT2B15. Hum Mutat 31:99-107, 2010. PMC2922057
*Sun C, Olopade OI, Di Rienzo A. rs2981582 is associated with FGFR2 expression in normal breast.
Cancer Genet Cytogenet 197:193-4, 2010. PMC2831800
Page 5
*Sun C, Southard C, Olopade OI, Di Rienzo A. Differential allelic expression of c.1568C > A at UGT2B15 is
due to variation in a novel cis-regulatory element in the 3'UTR. Gene 481:24-8, 2011. PMC3105206
*Sun C, Huo D, Southard C, Nemesure B, Hennis A, Cristina Leske M, Wu SY, Witonsky DB, Olopade OI,
Di Rienzo A. A signature of balancing selection in the region upstream to the human UGT2B4 gene and
implications for breast cancer risk. Hum Genet 130:767-75, 2011.
*Sun C, Southard C, Huo D, Hernandez RD, Witonsky DB, Olopade OI, Di Rienzo A. SNP discovery,
expression and cis-regulatory variation in the UGT2B genes. Pharmacogenomics J 12:287-96, 2012.
*Sun C, Huo D, Nemesure B, Hennis A, Leske MC, Wu SY, Niu Q, Olopade OI, Di Rienzo A. Lack of
association between common UGT2B nonsynonymous single-nucleotide polymorphisms and breast cancer
in populations of African ancestry. Int J Cancer 130:2740-2, 2012. PMC3268011
M. Eileen Dolan, PhD
Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME. Genetic variants associated with carboplatin-induced
cytotoxicity in cell lines derived from Africans. Mol Cancer Ther 7:3038-46, 2008. PMC2743011
Zhang W, Huang RS, Dolan ME. Cell-based models for discovery of pharmacogenomic markers of anticancer
agent toxicity. Trends Cancer Res 4:1-13, 2008. PMC3076057
Huang RS, Chen P, Wisel S, Duan S, Zhang W, Cook EH, Das S, Cox NJ, Dolan ME. Population-specific
GSTM1 copy number variation. Hum Mol Genet 18:366-72, 2009. PMC2722188
*Shukla SJ, Duan S, Wu X, Badner JA, Kasza K, Dolan ME. Whole-genome approach implicates CD44 in
cellular resistance to carboplatin. Hum Genomics 3:128-42, 2009. PMC2683878
O’Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of
chemotherapy. Clin Cancer Res 15:4806-14, 2009. PMC2774468
Zhang W, Dolan ME. Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des 15:378295, 2009. PMC2782819
Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H, Dolan ME.
Pharmacogenomic discovery using cell-based models. Pharmacol Rev 61:413-29, 2009. PMC2802425
*Pinto N, Ludeman SM, Dolan ME. Drug focus: pharmacogenetic studies related to cyclophosphamide-based
therapy. Pharmacogenomics 10:1897-903, 2009. PMC2820268
*Duan S, Mi S, Zhang W, Dolan ME. Comprehensive analysis of the impact of SNPs and CNVs on human
microRNAs and their regulatory genes. RNA Biol 6:412-25, 2009. PMC2783774
*Gamazon ER, Zhang W, Huang RS, Dolan ME, Cox NJ. A pharmacogene database enhanced by the 1000
genomes project. Pharmacogenet Genomics 19:829-32, 2009. PMC2935084
Zhang W, Dolan ME. Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery.
Pharmacogenomics 1:249-56, 2010. PMC2833269
Huang RS, Dolan ME. Approaches to discovery of pharmacogenomic markers in oncology: 2000-2010-2020.
Pharmacogenomics 11:471-4, 2010. PMC2864525
*Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs are more likely to be
eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 6:e1000888, 2010. PMC2848547
*Gamazon ER, Zhang W, Dolan ME, Cox NJ. Comprehensive survey of SNPs in the affymetrix exon array
using the 1000 genomes dataset. PLoS One 5:e9366, 2010. PMC2826392
*Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, Dolan ME, Cox NJ. SCAN: SNP
and copy number annotation. Bioinformatics 26:259-62, 2010. PMC2852202
Gamazon ER, Duan S, Zhang W, Huang RS, Kistner EO, Dolan ME, Cox NJ. PACdb: a database for cellbased pharmacogenomics. Pharmacogenet Genomics 20:269-73, 2010. PMC2914089
O'Donnell PH, Gamazon E, Zhang W, Stark AL, Kistner-Griffin EO, Huang RS, Dolan ME. Population
differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet
Genomics 20:327-37, 2010. PMC2908307
*Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are
enriched in expression quantitative trait loci. Proc Natl Acad Sci USA 107:9287-92, 2010. PMC2889115
*Stark AL, Zhang W, Mi S, Duan S, O’Donnell PH, Huang RS, Dolan ME. Heritable and non-genetic factors as
variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J 10:505-12,
2010. PMC2975793
Gamazon ER, Im HK, Duan S, Lussier YA, Cox NJ, Dolan ME, Zhang W. Exprtarget: an integrative approach
to predicting human microRNA targets. PLoS One 5:e13534, 2010. PMC2958831
Zhang W, Dolan ME. Emerging role of microRNAs in drug response. Curr Opin Mol Ther 12:695-702, 2010.
PMC3233195
Page 6
Stark AL, Zhang W, O’Donnell PH, Beiswanger CM, Huang RS, Cox NJ, Dolan ME. Population differences in
rate of proliferation of international HapMap cell lines. Am J Hum Genet 87:829-33, 2010. PMC2997375
Ziliak D, O’Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE,
Cohen EE, Dolan ME, Huang RS. Germline polymorphisms discovered via a cell-based genome-wide
approach predict platinum response in head and neck cancers. Transl Res 157:265-72, 2011.
PMC3079878
Gamazon ER, Im HK, O’Donnell PH, Ziliak D, Stark AL, Cox NJ, Dolan ME, Huang RS. Comprehensive
evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther 10:472-80,
2011. PMC3079551
Wen Y, Gorsic LK, Wheeler HE, Ziliak DM, Huang RS, Dolan ME. Chemotherapeutic-induced apoptosis: a
phenotype for pharmacogenomics studies. Pharmacogenetics Genomics 21:476-88, 2011. PMC3134538
Gamazon ER, Huang RS, Dolan ME, Cox NJ. Copy number polymorphisms and anticancer
pharmacogenomics. Genome Biol 12:R46, 2011. PMC3219969
Huang RS, Gamazon ER, Ziliak D, Wen Y, Im HK, Zhang W, Wing C, Duan S, Bleibel WK, Cox NJ, Dolan ME.
Population differences in microRNA expression and biological implications. RNA Biol 8:692-701, 2011.
PMC3225983
Huang RS, Johnatty SE, Gamazon ER, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S,
O’Donnell PH, Fraiman YS, Das S, Cox NJ, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall E,
Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E,
Vergote I, Gross J, Karlan BY, deFazio A, Chenevix-Trench G, Australian Ovarian Cancer Study Group,
Dolan ME. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and
analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 17:5490-500, 2011.
PMC3160494
Wheeler HE, Gorsic LK, Welsh M, Stark AL, Gamazon ER, Cox NJ, Dolan ME. Genome-wide local ancestry
approach identifies genes and variants associated with chemotherapeutic susceptibility in African
Americans. PLoS One 6:e21920, 2011. PMC3130766
Wilke RA, Dolan ME. Genetics and variable drug response. JAMA 306:306-7, 2011. PMC3539154
Innocenti F, Cox NJ, Dolan ME. The use of genomic information to optimize cancer chemotherapy. Semin
Oncol 38:186-95, 2011. PMC3076508
Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab
12:487-97, 2011. PMC3110519
Im HK, Gamazon ER, Stark AL, Huang RS, Cox NJ, Dolan ME. Mixed effects modeling of proliferation rates in
cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet 8:e1002525, 2012.
PMC3276560
O’Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, Gorsic L, Im HK, Huang RS, Cox NJ,
Dolan ME. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer
118:4063-73, 2012. PMC3413892
*Njiaju UO, Gamazon ER, Gorsic LK, Delaney SM, Wheeler HE, Im HK, Dolan ME. Whole-genome studies
identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics 22:498507, 2012. PMC3376193
Leandro-Garcia LJ, Leskela S, Jara C, Green H, Avall-Lundqvist E, Wheeler HE, Dolan ME, Inglada-Perez L,
Maliszewska A, de Cubas AA, Comino-Mendez I, Mancikova V, Cascon A, Robledo M, RodriguezAntona C. Regulatory polymorphisms in tubulin IIa are associated with paclitaxel-induced peripheral
neuropathy. Clin Cancer Res 18:4441-8, 2012. PMC3664665
Wheeler HE, Dolan ME. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation.
Pharmacogenomics 13:55-70, 2012. PMC3292907
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T,
Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c inhibits
human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 4:1393, 2013.
PMC3723106
Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I,
Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, Cox NJ,
Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture
of paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 19:491-9, 2013. PMC3549006
Page 7
Wheeler HE, Gamazon ER, Stark AL, O’Donnell PH, Gorsic LK, Huang RS, Cox NJ, Dolan ME. Genome-wide
meta-analysis identifies variants associated with platinating agent susceptibility across populations.
Pharmacogenomics J 13:35-43, 2013. PMC3370147
Gamazon E, Huang RS, Dolan ME, Cox N, Im HK. Integrative genomics: quantifying significance of
phenotype-genotype relationships from multiple sources of high-throughput data. Front Genet 3:202, 2013.
PMC368276
˄
Karen Drukker
*Drukker K, Gruszauskas NP, Sennett CA, Giger ML. Breast US computer-aided diagnosis workstation:
performance with a large clinical diagnostic population. Radiology 248:392-7, 2008. PMC2797650
*Gruszauskas NP, Drukker K, Giger ML, Sennett CA, Pesce LL. Performance of breast ultrasound computeraided diagnosis: dependence on image selection. Acad Radiol 15:1234-45, 2008. PMC2567418
*Drukker K, Sennett CA, Giger ML. Automated method for improving system performance of computer-aided
diagnosis in breast ultrasound. IEEE Trans Med Imaging 28:122-8, 2009.
Jamieson AR, Giger ML, Drukker K, Li H, Yuan Y, Bhooshan N. Exploring non-linear feature space dimension
reduction and data representation in breast CADx with Laplacian eigenmaps and t-SNE. Med Phys 37:33951, 2010. PMC2807447
Jamieson AR, Giger ML, Drukker K, Pesce LL. Enhancement of breast CADx with unlabeled data. Med Phys
37:4155-72, 2010. PMC2921421
*Drukker K, Pesce L, Giger M. Repeatability in computer-aided diagnosis: application to breast cancer
diagnosis on sonography. Med Phys 37:2659-69, 2010. PMC2885941
Chen W, Metz CE, Giger ML, Drukker K. A novel hybrid linear/nonlinear classifier for two-class classification:
theory, algorithm, and applications. IEEE Trans Med Imaging 29:428-41, 2010.
*Drukker K, Horsch KJ, Pesce LL, Giger ML. Interreader scoring variability in an observer study using dualmodality imaging for breast cancer detection in women with dense breasts. Acad Radiol 20:847-53, 2013.
˄
Shinwei Duan, PhD
Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME. Genetic variants associated with carboplatin-induced
cytotoxicity in cell lines derived from Africans. Mol Cancer Ther 7:3038-46, 2008. PMC2743011
Huang RS, Chen P, Wisel S, Duan S, Zhang W, Cook EH, Das S, Cox NJ, Dolan ME. Population-specific
GSTM1 copy number variation. Hum Mol Genet 18:366-72, 2009. PMC2722188
*Shukla SJ, Duan S, Wu X, Badner JA, Kasza K, Dolan ME. Whole-genome approach implicates CD44 in
cellular resistance to carboplatin. Hum Genomics 3:128-42, 2009. PMC2683878
*Duan S, Mi S, Zhang W, Dolan ME. Comprehensive analysis of the impact of SNPs and CNVs on human
microRNAs and their regulatory genes. RNA Biol 6:412-25, 2009. PMC2783774
*Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, Dolan ME, Cox NJ. SCAN: SNP
and copy number annotation. Bioinformatics 26:259-62, 2010. PMC2852202
Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait associated SNPs are more likely to be
eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 6:e1000888, 2010. PMC2848547
Gamazon ER, Duan S, Zhang W, Huang RS, Kistner EO, Dolan ME, Cox NJ. PACdb: a database for cellbased pharmacogenomics. Pharmacogenet Genomics 20:269-73, 2010. PMC2914089
Stark AL, Zhang W, Mi S, Duan S, O’Donnell PH, Huang RS, Dolan ME. Heritable and non-genetic factors as
variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J 10:505-12,
2010. PMC2975793
Gamazon ER, Im HK, Duan S, Lussier YA, Cox NJ, Dolan ME, Zhang W. Exprtarget: an integrative approach
to predicting human microRNA targets. PLoS One 5:e13534, 2010. PMC2958831
Huang RS, Gamazon ER, Ziliak D, Wen Y, Im HK, Zhang W, Wing C, Duan S, Bleibel WK, Cox NJ, Dolan ME.
Population differences in microRNA expression and biological implications. RNA Biol 8:692-701, 2011.
PMC3225983
Huang RS, Johnatty SE, Gamazon ER, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S,
O’Donnell PH, Fraiman YS, Das S, Cox NJ, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall E,
Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E,
Vergote I, Gross J, Karlan BY, deFazio A, Chenevix-Trench G, Australian Ovarian Cancer Study Group,
Dolan ME. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and
analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 17:5490-500, 2011.
PMC3160494
Page 8
˄
James D. Fackenthal, PhD
Wang X, Liu L, Fackenthal J, Cummings S, Olopade OI, Hope K, Silverstein JC, Olopade OI. Translational
integrity and continuity: personalized biomedical data integration. J Biomed Inform 42:100-12, 2009.
PMC2675887
Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, Jonasdottir A, Besenbacher S,
Kostic JP, Fackenthal JD, Huo D, Adebamowo C, Ogundiran T, Olson JE, Fredericksen ZS, Wang X,
Look MP, Sieuwerts AM, Martens JW, Pajares I, Garcia-Prats MD, Ramon-Cajal JM, de Juan A,
Panadero A, Ortega E, Aben KK, Vermeulen SH, Asadzadeh F, van Engelenburg KC, Margolin S,
Shen CY, Wu PE, Försti A, Lenner P, Henriksson R, Johansson R, Enquist K, Hallmans G, Jonsson T,
Sigurdsson H, Alexiusdottir K, Gudmundsson J, Sigurdsson A, Frigge ML, Gudmundsson L,
Kristjansson K, Halldorsson BV, Styrkarsdottir U, Gulcher JR, Hemminki K, Lindblom A, Kiemeney LA,
Mayordomo JI, Foekens JA, Couch FJ, Olopade OI, Gudbjartsson DF, Torsteinsdottir U, Rafnar T,
Johannsson OT, Stefansson. Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer
susceptibility locus. PLoS Genet 6:e1001029, 2010. PMC2907678
Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos, F, Burrill DR, Niu Q, Huo D, Sveen WE, Ogundiran T,
Adebamowo C, Odetunde A, Falusi AG, Olopade OI. High prevalence of BRCA1 and BRCA2 mutations in
unselected Nigerian breast cancer patients. Int J Cancer 131:1114-23, 2012.
Gini Fleming, MD
Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC,
Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic
breast cancer. Breast Cancer Res Treat 136:355-63, 2012. PMC3658119
Yang-Xin Fu, MD, PhD
Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK,
Greene M, Liu Y, Tang J, Wang S, Fu YX. The therapeutic effect of anti-HER2/neu antibody depends on
both innate and adaptive immunity. Cancer Cell 18:160-70, 2010. PMC2923645
˄
Maryellen Giger, PhD
*Drukker K, Gruszauskas NP, Sennett CA, Giger ML. Breast US computer-aided diagnosis workstation:
performance with a large clinical diagnostic population. Radiology 248:392-7, 2008. PMC2797650
*Gruszauskas NP, Drukker K, Giger ML, Sennett CA, Pesce LL. Performance of breast ultrasound computeraided diagnosis: dependence on image selection. Acad Radiol 15:1234-45, 2008. PMC2567418
*Drukker K, Sennett CA, Giger ML. Automated method for improving system performance of computer-aided
diagnosis in breast ultrasound. IEEE Trans Med Imaging 28:122-8, 2009.
*Li H, Giger ML, Yuan Y, Chen W, Lan L, Jamieson AR, Sennett CA, Janson SA. Evaluation of computer-aided
diagnosis on a large clinical full-field digital mammographic dataset. Acad Radiol 15:1437-45, 2008.
PMC2597106
Yuan Y, Giger ML, Li H, Sennett C. Correlative feature analysis on FFDM. Med Phys 35:5490-500, 2008.
PMC2736721
*Li H, Giger ML, Olopade OI, Chinander MR. Power spectral analysis of mammographic parenchymal patterns
for breast cancer risk assessment. J Digit Imaging 21:145-52, 2008. PMC3043857
Li H, Giger ML, Yuan Y, Jansen SA, Lan L, Bhooshan N, Newstead GM. Computerized breast parenchymal
analysis on DCE-MRI. Proc SPIE 7260, Medical Imaging 2009: Computer-Aided Diagnosis 72600N, 2009.
*Bhooshan N, Giger ML, Jansen S, Li H, Lan L, Newstead G. Cancerous breast lesions on dynamic contrastenhanced MR images: computerized characterization for image-based prognostic markers. Radiology
254:680-90, 2010. PMC2826695
Jamieson AR, Giger ML, Drukker K, Li H, Yuan Y, Bhooshan N. Exploring non-linear feature space dimension
reduction and data representation in breast CADx with Laplacian eigenmaps and t-SNE. Med Phys 37:33951, 2010. PMC2807447
Chen W, Metz CE, Giger ML, Drukker K. A novel hybrid linear/nonlinear classifier for two-class classification:
theory, algorithm, and applications. IEEE Trans Med Imag 29:428-41, 2010.
Chen W, Giger ML, Newstead GM, Bick U, Sanaz SA, Li H, Lan L. Computerized assessment of breast lesion
malignancy using DCE-MRI robustness study on two independent clinical datasets from two
manufacturers. Acad Radiol 17:822-9, 2010. PMC2907891
Page 9
*Drukker K, Pesce L, Giger M. Repeatability in computer-aided diagnosis: application to breast cancer
diagnosis on sonography. Med Phys 37:659-69, 2010. PMC2885941
Yuan Y, Giger ML, Li H, Bhooshan N, Sennett CA. Multimodality computer-aided breast cancer diagnosis with
FFDM and DCE-MRI. Acad Radiol 17:1158-67, 2010.
Jamieson AR, Giger ML, Drukker K, Pesce LL. Enhancement of breast CADx with unlabeled data. Med Phys
37:4155-72, 2010. PMC2921421
*Jansen SA, Lin VC, Giger ML, Li H, Karczmar GS, Newstead GM. Normal parenchymal enhancement
patterns in women undergoing MR screening of the breast. Eur Radiol 21:1374-82, 2011.
Bhooshan N, Giger M, Lan L, Li H, Marquez A, Shimauchi A, Newstead GM. Combined use of T2-weighted
MRI and T1-weighted dynamic contrast-enhanced MRI in the automated analysis of breast lesions. Magn
Reson Med 66:555-64, 2011.
Bhooshan N, Giger M, Edwards D, Yuan Y, Jansen S, Li H, Lan L, Sattar H, Newstead G. Computerized threeclass classification of MRI-based prognostic markers for breast cancer. Phys Med Biol 56:5995-6008,
2011.
Li H, Giger ML, Lan L, Bancroft Brown J, MacMahon A, Mussman M, Olopade OI, Sennett C. Computerized
analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital
mammograms: robustness study with two high-risk datasets. J Digit Imaging 25:591-8, 2012.
PMC3447101
Yuan Y, Giger ML, Li H, Bhooshan N, Sennett CA. Correlative analysis of FFDM and DCE-MRI for improved
breast CADx. J Med Biol Eng 32:42-50, 2012.
Drukker K, Horsch KJ, Pesce LL, Giger ML. Interreader scoring variability in an observer study using dualmodality imaging for breast cancer detection in women with dense breasts. Acad Radiol 20:847-53, 2013.
Geoffrey Greene, PhD
Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM,
Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast
cancer cell invasion. Breast Cancer Res Treat 137:373-82, 2013. PMC3583223
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T,
Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c inhibits
human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 4:1393, 2013.
PMC3723106
˄
Tatyana A. Grushko, PhD
Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine.
Clin Cancer Res 14:7988-99, 2008.
Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O,
Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI. Population
differences in breast cancer: survey in indigenous African women reveals over-representation of triplenegative breast cancer. J Clin Oncol 27:4515-21, 2009. PMC2754904
Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C,
Nobel A, Kristensen VN, Børresen-Dale AL, Olopade OI, Perou CM. 2011. Basal-like breast cancer DNA
copy number losses identify genes involved in genomic instability, response to therapy, and patient
survival. Breast Cancer Res Treat 133:865-80, 2012. PMC3387500
Dezheng Huo, PhD
Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine.
Clin Cancer Res 14:7988-99, 2008.
Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O,
Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI. Population
differences in breast cancer: survey in indigenous African women reveals over-representation of triplenegative breast cancer. J Clin Oncol 27:4515-21, 2009. PMC2754904
*Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway
activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176:2911-20,
2010. PMC2877852
Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI. Screening RAD51C nucleotide alterations in patients
with a family history of breast and ovarian cancer. Breast Cancer Res Treat 124:857-61, 2010.
Page 10
Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, Jonasdottir A, Besenbacher S,
Kostic JP, Fackenthal JD, Huo D, Adebamowo C, Ogundiran T, Olson JE, Fredericksen ZS, Wang X,
Look MP, Sieuwerts AM, Martens JW, Pajares I, Garcia-Prats MD, Ramon-Cajal JM, de Juan A,
Panadero A, Ortega E, Aben KK, Vermeulen SH, Asadzadeh F, van Engelenburg KC, Margolin S,
Shen CY, Wu PE, Försti A, Lenner P, Henriksson R, Johansson R, Enquist K, Hallmans G, Jonsson T,
Sigurdsson H, Alexiusdottir K, Gudmundsson J, Sigurdsson A, Frigge ML, Gudmundsson L,
Kristjansson K, Halldorsson BV, Styrkarsdottir U, Gulcher JR, Hemminki K, Lindblom A, Kiemeney LA,
Mayordomo JI, Foekens JA, Couch FJ, Olopade OI, Gudbjartsson DF, Thorsteinsdottir U, Rafnar T,
Johannsson OT, Stefansson K. Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer
susceptibility locus. PloS Genet 6:e1001029, 2010. PMC2908678
Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyesegun R, Akang E, Adebamowo C, Olopade OI.
Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol 172:682-90,
2010. PMC2950817
*Sun C, Huo D, Southard C, Nemesure B, Hennis A, Cristina Leske M, Wu SY, Witonsky DB, Olopade OI,
Di Rienzo A. A signature of balancing selection in the region upstream to the human UGT2B4 gene and
implications for breast cancer risk. Hum Genet 130:767-75, 2011.
Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y,
Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ. Proliferating
macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical
outcome. Breast Cancer Res Treat 128:703-11, 2011.
Chen Y, Xu J, Borowicz S, Collins C, Huo D, Olopade OI. c-Myc activates BRCA1 gene expression through
distal promoter elements in breast cancer cells. BMC Cancer 11:246, 2011. PMC3141769
*Sun C, Huo D, Nemesure B, Hennis A, Leske MC, Wu SY, Niu Q, Olopade OI, Di Rienzo A. Lack of
association between common UGT2B nonsynonymous single-nucleotide polymorphisms and breast cancer
in populations of African ancestry. Int J Cancer 130:2740-2, 2012. PMC3268011
*Huo D, Melkonian S, Rathouz PJ, Khramtsov A, Olopade OI. Concordance in histological and biological
parameters between first and second primary breast cancers. Cancer 117:907-15, 2011. PMC3022996
*Zheng Y, Zhang J, Niu Q, Huo D, Olopade OI. Novel germline PALB2 truncating mutations in African
American breast cancer patients. Cancer 118:1362-70, 2012. PMC3244533
*Sylvester BE, Huo D, Khramtsov A, Zhang J, Smalling RV, Olugbile S, Polite BN, Olopade OI. Molecular
analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res 18:3509, 2012. PMC3272273
*Zheng Y, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Rebbeck TR, Simon MS, John EM,
Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, Niu Q, Zhang J, Cox NJ, Olopade OI, Huo D. Lack of
association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast
cancer in women of African ancestry. Breast Cancer Res Treat 132:341-5, 2012. PMC3670987
*Zheng Y, Huo D, Zhang J, Yoshimatsu TF, Niu Q, Olopade OI. Microsatellites in the estrogen receptor (ESR1,
ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian
women. PLoS One 7:e40494, 2012. PMC3394707
*Sun C, Southard C, Huo D, Hernandez RD, Witonsky DB, Olopade OI, Di Rienzo A. SNP discovery,
expression and cis-regulatory variation in the UGT2B genes. Pharmacogenomics J 12:287-96, 2012.
Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C,
Nobel A, Kristensen VN, Borresen-Dale AL, Olopade OI, Perou CM. Basal-like breast cancer DNA copy
number losses identify genes involved in genomic instability, response to therapy, and patient survival.
Breast Cancer Res Treat 133:865-80, 2012. PMC3387500
Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyesegun R, Akang E, Adebamowo C, Olopade OI. Body
fat distribution and breast cancer risk: findings from the Nigerian breast cancer study. Cancer Causes
Control 23:565-74, 2012.
Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos, F, Burrill DR, Niu Q, Huo D, Sveen WE, Ogundiran T,
Adebamowo C, Odetunde A, Falusi AG, Olopade OI. High prevalence of BRCA1 and BRCA2 mutations in
unselected Nigerian breast cancer patients. Int J Cancer 131:1114-23, 2012.
Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC,
Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic
breast cancer. Breast Cancer Res Treat 136:355-63, 2012. PMC3658119
Page 11
Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM,
Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast
cancer cell invasion. Breast Cancer Res Treat 137:373-82, 2013. PMC3583223
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T,
Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c inhibits
human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 4:1393, 2013.
PMC3723106
Chen F, Chen GK, Stram DO, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Palmer JR,
Hu JJ, Rebbeck TR, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Press MF, Ruiz-Narvaez EA,
Deming SL, Rodriguez-Gil JL, Demichele A, Chanock SJ, Blot W, Signorello L, Cai Q, Li G, Long J, Huo D,
Zheng Y, Cox NJ, Olopade OI, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Simon MS,
Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, Hutter CM, Young A, Kooperberg C, Peters U,
Rhie SK, Wan P, Sheng X, Pooler LC, Van Den Berg DJ, Le Marchand L, Kolonel LN, Henderson BE,
Haiman CA. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet
132:39-48, 2013. PMC3749077
Zheng Y, Ogundiran TO, Falusi AG, Nathanson KL, John EM, Hennis AJ, Ambs S, Domchek SM, Rebbeck
TR, Simon MS, Nemesure B, Wu SY, Leske MC, Odetunde A, Niu Q, Zhang J, Afolabi C, Gamazon ER,
Cox NJ, Olopade CO, Olufunmilayo OI, Huo D. Fine mapping of breast cancer genome-wide association
studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis 34:1520-8,
2013. PMC3697898
Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. Hormone replacement therapy and breast cancer:
heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst 105:1365-72, 2013.
Gregory Karczmar, PhD
*Jansen SA, Shimauchi A, Zak L, Fan X, Wood AM, Karczmar GS, Newstead GM. Kinetic curves of malignant
lesions are not consistent across MRI systems: Need for improved standardization of breast dynamic
contrast-enhanced MRI acquisition. AJR 193:832-9, 2009. PMC2938789
Foxley S, Fan X, Mustafi D, Haney C, Zamora M, Markiewicz E, Medved M, Wood AM, Karczmar GS.
Sensitivity to tumor microvasculature without contrast agents in high spectral and spatial resolution MR
images. Magn Reson Med 61:291-298, 2009. PMC3370261
*Medved M, Newstead GM, Fan X, Du YP, Olopade OI, Shimauchi A, Zamora MA, Karczmar GS. Fourier
component imaging of water resonance in human breast provides markers for malignancy.
Phys Med Biol 54:5767-79, 2009. PMC2941263
*Jansen SA, Conzen SD, Fan X, Markiewicz EJ, Newstead GM, Karczmar GS. Magnetic resonance imaging of
the natural history of in situ mammary neoplasia in transgenic mice: a pilot study. Breast Cancer Res
11:R65, 2009. PMC2790840
Fan X, Karczmar GS. A new approach to analysis of the impulse response function (IRF) in dynamic contrastenhanced MRI (DCEMRI): a simulation study. Magn Reson Med 62:229-39, 2009. PMC2927981
*Medved M, Ivancevic MK, Olopade OI, Newstead GM, Karczmar GS. Echo-planar spectroscopic imaging
(EPSI) of the water resonance structure in human breast using Sensitivity Encoding (SENSE).
Magn Reson Med 63:1557-63, 2010. PMC3065325
*Fan X, Haney CR, Mustafi D, Yang C, Zamora M, Markiewicz E, Karczmar GS. Use of a reference tissue and
blood vessel to measure the arterial input function in DCEMRI. Magn Reson Med 64:1821-6, 2010.
PMC2992085
*Medved M, Newstead GM, Abe H, Olopade OI, Shimauchi A, Zamora MA, Karczmar GS. Clinical
implementation of a multislice high spectral and spatial resolution-based MRI sequence to achieve
unilateral full-breast coverage. Magn Reson Imaging 28:16-21, 2010. PMC2789876
Jansen SA, Fan X, Medved M, Abe H, Shimauchi A, Yang C, Zamora M, Foxley S, Olopade OI, Karczmar GS,
Newstead GM. Characterizing early contrast uptake of ductal carcinoma in situ with high temporal
resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys Med Biol 55:N473-85, 2010.
*Heisen M, Fan X, Buurman J, van Riel NA, Karczmar GS, ter Haar Romeny BM. The use of a reference tissue
arterial input function with low-temporal-resolution DCE-MRI data. Phys Med Biol 55:4871-83, 2010.
*Medved M, Fan X, Abe H, Newstead GM, Wood AM, Shimauchi A, Kulkarni K, Ivancevic MK, Pesce LL,
Olopade OI, Karczmar GS. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of
non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fatsuppressed images. Acad Radiol 18:1467-74, 2011. PMC3210583
Page 12
*Jansen SA, Shimauchi A, Zak L, Fan X, Karczmar GS, Newstead GM. The diverse pathology and kinetics of
mass, nonmass, and focus enhancement on MR imaging of the breast. J Magn Reson Imaging 33:1382-9,
2011. PMC3098464
*Jansen SA, Lin VC, Giger ML, Li H, Karczmar GS, Newstead GM. Normal parenchymal enhancement
patterns in women undergoing MR screening of the breast. Eur Radiol 21:1374-82, 2011.
*Jansen SA, Conzen SD, Fan X, Markiewicz E, Krausz T, Newstead GM, Karczmar GS. In vivo MRI of early
stage mammary cancers and the normal mouse mammary gland. NMR Biomed 24:880-7, 2011.
*Hipp E, Fan X, Jansen SA, Markiewicz EJ, Vosicky J, Newstead GM, Conzen SD, Krausz T, Karczmar GS.
T(2) relaxation times of intraductal murine mammary cancer, invasive mammary cancer, and normal
mammary gland. Med Phys 39:1309-13, 2012. PMC3292598
Wood AM, Medved M, Bacchus ID, Al-Hallaq HA, Shimauchi A, Newstead GM, Olopade OI,
Venkataraman SS, Ivancevic MK, Karczmar GS. Classification of breast lesions pre-contrast injection using
water resonance lineshape analysis. NMR Biomed 26:569-77, 2013.
Swati Kulkarni, MD
Abe H, Schmidt RA, Shah RN, Shimauchi A, Kulkarni K, Sennett CA, Newstead GM. MR-directed (SecondLook) ultrasound examination for breast lesions detected initially on MRI: MR and sonographic findings.
AJR Am J Roentgenol 194:370-7, 2010.
*Medved M, Fan X, Abe H, Newstead GM, Wood AM, Shimauchi A, Kulkarni K, Ivancevic MK, Pesce LL,
Olopade OI, Karczmar GS. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of
non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fatsuppressed images. Acad Radiol 18:1467-74, 2011. PMC3210583
Huiping Liu, MD, PhD
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T,
Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c inhibits
human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 4:1393, 2013.
PMC3723106
Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM,
Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast
cancer cell invasion. Breast Cancer Res Treat 137:373-82, 2013. PMC3583223
Rita Nanda, MD
Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine.
Clin Cancer Res 14:7988-99, 2008.
Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O,
Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI. Population
differences in breast cancer: survey in indigenous African women reveals over-representation of triplenegative breast cancer. J Clin Oncol 27:4515-21, 2009. PMC2754904
Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC,
Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic
breast cancer. Breast Cancer Res Treat 136:355-63, 2012. PMC3658119
Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A,
Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M,
Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J,
Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L.
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug
development. J Clin Oncol 30:4584-6, 2012.
De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K,
Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES. Magnetic resonance imaging as a predictor of
pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer
Translational Breast Cancer Research Consortium trial 017. Cancer 119:1776-83, 2013.
Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG,
Gutierrez C, Schiff R, Osborne CK, Chang JC. Multicenter phase II study of neoadjuvant lapatinib and
trastuzumab with hormonal therapy and without chemotherapy in patients with HER2 overexpressing
breast cancer: TBCRC 006. J Clin Oncol 31:1726-31, 2013. PMC3641695
Page 13
˄
Gillian Newstead, MD
*Medved M, Newstead GM, Fan X, Du YP, Olopade OI, Shimauchi A, Zamora MA, Karczmar GS. Fourier
component imaging of water resonance in the human breast provides markers for malignancy.
Phys Med Biol 54:5767-79, 2009. PMC2941263
*Jansen SA, Conzen SD, Fan X, Markiewicz EJ, Newstead GM, Karczmar GS. Magnetic resonance imaging of
the natural history of in situ mammary neoplasia in transgenic mice: A pilot study. Breast Cancer Res
11:R65, 2009. PMC2790840
Li H, Giger ML, Yuan Y, Jansen SA, Lan L, Bhooshan N, Newstead GM. Computerized breast parenchymal
analysis on DCE-MRI. Proc SPIE 7260, Medical Imaging 2009: Computer-Aided Diagnosis 72600N, 2009.
*Jansen SA, Shimauchi A, Zak L, Fan X, Wood AM, Karczmar GS, Newstead GM. Kinetic curves of malignant
lesions are not consistent across MRI systems: need for improved standardization of breast dynamic
contrast-enhanced MRI acquisition. AJR Am J Roentgenol 193:832-9, 2009. PMC2938789
Abe H, Schmidt RA, Shah RN, Shimauchi A, Kulkarni K, Sennett CA, Newstead GM. MR-directed (SecondLook) ultrasound examination for breast lesions detected initially on MRI: MR and sonographic findings.
AJR Am J Roentgenol 194:370-7, 2010.
Jansen SA, Fan X, Medved M, Abe H, Shimauchi A, Yang C, Zamora M, Foxley S, Olopade OI, Karczmar GS,
Newstead GM. Characterizing early contrast uptake of ductal carcinoma in situ with high temporal
resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys Med Biol 55:N473-85, 2010.
*Medved M, Newstead GM, Abe H, Olopade OI, Shimauchi A, Zamora MA, Karczmar GS. Clinical
implementation of a multislice high spectral and spatial resolution-based MRI sequence to achieve
unilateral full-breast coverage. Magn Reson Imag 28:16-21, 2010. PMC2789876
*Bhooshan N, Giger ML, Jansen SA, Li H, Lan L, Newstead GM. Cancerous breast lesions on dynamic
contrast-enhanced MR images: Computerized characterization for image-based prognostic markers.
Radiology 254:680-90, 2010. PMC2826695
*Medved M, Ivancevic MK, Olopade OI, Newstead GM, Karczmar GS. Echo-planar spectroscopic imaging
(EPSI) of the water resonance structure in human breast using sensitivity encoding (SENSE).
Magn Reson Med 63:1557-1563, 2010. PMC3065325
Chen W, Giger ML, Newstead GM, Bick U, Jansen SA, Li H, Lan L. Computerized assessment of breast lesion
malignancy using DCE-MRI robustness study on two independent clinical datasets from two
manufacturers. Acad Radiol 17:822-829, 2010. PMC2907891
*Jansen SA, Lin VC, Giger ML, Li H, Karczmar GS, Newstead GM. Normal parenchymal enhancement
patterns in women undergoing MR screening of the breast. Eur Radiol 21:1374-82, 2011.
*Jansen SA, Shimauchi A, Zak L, Fan X, Karczmar GS, Newstead GM. The diverse pathology and kinetics of
mass, nonmass, and focus enhancement on MR imaging of the breast. J Magn Reson Imaging 33:1382-9,
2011. PMC3098464
Bhooshan N, Giger M, Edwards D, Yuan Y, Jansen S, Li H, Lan L, Sattar H, Newstead G. Computerized threeclass classification of MRI-based prognostic markers for breast cancer. Phys Med Biol 56:5995-6008,
2011.
Bhooshan N, Giger M, Lan L, Li H, Marquez A, Shimauchi A, Newstead GM. Combined use of T2-weighted
MRI and T1-weighted dynamic contrast-enhanced MRI in the automated analysis of breast lesions. Magn
Reson Med 66:555-64, 2011.
*Medved M, Fan X, Abe H, Newstead GM, Wood AM, Shimauchi A, Kulkarni K, Ivancevic MK, Pesce LL,
Olopade OI, Karczmar GS. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of
non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fatsuppressed images. Acad Radiol 18:1467-74, 2011. PMC3210583
*Jansen SA, Conzen SD, Fan X, Markiewicz E, Krausz T, Newstead GM, Karczmar GS. In vivo MRI of early
stage mammary cancers and the normal mouse mammary gland. NMR Biomed 24:880-7, 2011
*Hipp E, Fan X, Jansen SA, Markiewicz EJ, Vosicky J, Newstead GM, Conzen SD, Krausz T, Karczmar GS.
T(2) relaxation times of intraductal murine mammary cancer, invasive mammary cancer, and normal
mammary gland. Med Phys 39:1309-13, 2012. PMC3292598
Wood AM, Medved M, Bacchus ID, Al-Hallaq HA, Shimauchi A, Newstead GM, Olopade OI,
Venkataraman SS, Ivancevic MK, Karczmar GS. Classification of breast lesions pre-contrast injection using
water resonance lineshape analysis. NMR Biomed 26:569-77, 2013.
Page 14
Peter O’Donnell, MD
O’Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of
chemotherapy. Clin Cancer Res 15:4806-14, 2009. PMC2774468
O'Donnell PH, Gamazon E, Zhang W, Stark AL, Kistner-Griffin EO, Huang RS, Dolan ME. Population
differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet
Genomics 20:327-37, 2010. PMC2908307
Stark AL, Zhang W, Mi S, Duan S, O’Donnell PH, Huang RS, Dolan ME. Heritable and non-genetic factors as
variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J 10:505-12,
2010. PMC2975793
Stark AL, Zhang W, O’Donnell PH, Beiswanger CM, Huang RS, Cox NJ, Dolan ME. Population differences in
rate of proliferation of international HapMap cell lines. Am J Hum Genet 87:829-33, 2010. PMC2997375
Ziliak D, O’Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE,
Cohen EE, Dolan ME, Huang RS. Germline polymorphisms discovered via a cell-based genome-wide
approach predict platinum response in head and neck cancers. Transl Res 157:265-72, 2011.
PMC3079878
Gamazon ER, Im HK, O’Donnell PH, Ziliak D, Stark AL, Cox NJ, Dolan ME, Huang RS. Comprehensive
evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther 10:472-80,
2011. PMC3079551
Huang RS, Johnatty SE, Gamazon ER, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S,
O’Donnell PH, Fraiman YS, Das S, Cox NJ, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall E,
Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E,
Vergote I, Gross J, Karlan BY, deFazio A, Chenevix-Trench G, Australian Ovarian Cancer Study Group,
Dolan ME. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and
analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 17:5490-500, 2011.
PMC3160494
O’Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, Gorsic L, Im HK, Huang RS, Cox NJ, Dolan
ME. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer 118:406373, 2012. PMC3413892
Wheeler HE, Gamazon ER, Stark AL, O’Donnell PH, Gorsic LK, Huang RS, Cox NJ, Dolan ME. Genome-wide
meta-analysis identifies variants associated with platinating agent susceptibility across populations.
Pharmacogenomics J 13:35-43, 2013. PMC3370147
Mark Ratain, MD
Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I,
Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, Cox NJ,
Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture
of paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 19:491-9, 2013. PMC3549006
Husain Sattar, MD
Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK,
Greene M, Liu Y, Tang J, Wang S, Fu YX. The therapeutic effect of anti-HER2/neu antibody depends on
both innate and adaptive immunity. Cancer Cell 18:160-70, 2010. PMC2923645
Bhooshan N, Giger M, Edwards D, Yuan Y, Jansen S, Li H, Lan L, Sattar H, Newstead G. Computerized threeclass classification of MRI-based prognostic markers for breast cancer. Phys Med Biol 56:5995-6008,
2011.
Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC,
Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic
breast cancer. Breast Cancer Res Treat 136:355-63, 2012. PMC3658119
*Ulasov IV, Kaverina NV, Pytel P, Thaci B, Liu F, Hurst DR, Welch DR, Sattar HA, Olopade OI,
Baryshnikov AY, Kadagidze ZG, Lesniak MS. Clinical significance of KISS1 protein expression for brain
invasion and metastasis. Cancer 118:2096-105, 2012. PMC3674482
˄
Charlene Sennett, MD
*Drukker K, Gruszauskas NP, Sennett CA, Giger ML. Breast US computer-aided diagnosis workstation:
performance with a large clinical diagnostic population. Radiology 248:392-7, 2008. PMC2797650
Page 15
*Gruszauskas NP, Drukker K, Giger ML, Sennett CA, Pesce LL. Performance of breast ultrasound computeraided diagnosis: dependence on image selection. Acad Radiol 15:1234-45, 2008. PMC2567418
*Li H, Giger ML, Yuan Y, Chen W, Lan L, Jamieson AR, Sennett CA, Janson SA. Evaluation of computer-aided
diagnosis on a large clinical full-field digital mammographic dataset. Acad Radiol 15:1437-45, 2008.
PMC2597106
Yuan Y, Giger ML, Li H, Sennett C. Correlative feature analysis on FFDM. Med Phys 35:5490-500, 2008.
PMC2736721
*Drukker K, Sennett CA, Giger ML. Automated method for improving system performance of computer-aided
diagnosis in breast ultrasound. IEEE Trans Med Imaging 28:122-8, 2009.
Yuan Y, Giger ML, Li H, Bhooshan N, Sennett CA. Multimodality computer-aided breast cancer diagnosis with
FFDM and DCE-MRI. Acad Radiol 17:1158-67, 2010.
Abe H, Schmidt RA, Shah RN, Shimauchi A, Kulkarni K, Sennett CA, Newstead GM. MR-directed (SecondLook) ultrasound examination for breast lesions detected initially on MRI: MR and sonographic findings.
AJR Am J Roentgenol 194:370-7, 2010.
Li H, Giger ML, Lan L, Bancroft Brown J, Macmahon A, Mussman M, Olopade OI, Sennett C. Computerized
analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital
mammograms: robustness study with two high-risk datasets. J Digit Imaging 25:591-8, 2012.
PMC3447101
Yuan Y, Giger ML, Li H, Bhooshan N, Sennett CA. Correlative analysis of FFDM and DCE-MRI for improved
breast CADx. J Med Biol Eng 32:42-50, 2012.
˄
Xiaoming Wang, PhD
Wang X, Liu L, Fackenthal J, Cummings S, Cook M, Hope K, Silverstein J, Olopade OI. Translational integrity
and continuity: Personalized biomedical data integration. J Biomedical Informatics 42:100-112, 2009.
PMC2675887
Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, Jonasdottir A, Besenbacher S,
Kostic JP, Fackenthal JD, Huo D, Adebamowo C, Ogundiran T, Olson JE, Fredericksen ZS, Wang X,
Look MP, Sieuwerts AM, Martens JW, Pajares I, Garcia-Prats MD, Ramon-Cajal JM, de Juan A,
Panadero A, Ortega E, Aben KK, Vermeulen SH, Asadzadeh F, van Engelenburg KC, Margolin S, Shen CY,
Wu PE, Försti A, Lenner P, Henriksson R, Johansson R, Enquist K, Hallmans G, Jonsson T, Sigurdsson H,
Alexiusdottir K, Gudmundsson J, Sigurdsson A, Frigge ML, Gudmundsson L, Kristjansson K, Halldorsson
BV, Styrkarsdottir U, Gulcher JR, Hemminki K, Lindblom A, Kiemeney LA, Mayordomo JI, Foekens JA,
Couch FJ, Olopade OI, Gudbjartsson DF, Thorsteinsdottir U, Rafnar T, Johannsson OT, Stefansson K.
Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet
6:e1001029, 2010. PMC2908678
˄
Key Personnel that were previously on the Breast Cancer SPORE
Page 16